FDAnews Drug Daily Bulletin

Shire Phase II Study of MDD Adjunctive Therapy Vyvanse Capsules Meets Endpoints

Dec. 9, 2011
A A
Shire reported results from a Phase II trial of its adjunctive therapy Vyvanse capsules for patients suffering from major depressive disorder with the change in global executive composite T-score of the behavioral rating inventory of executive function - adult version assessment being the primary efficacy measure.
RTT News